Published in Bull Cancer on February 01, 2006
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol (2013) 2.73
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Career choices of medical students: a national survey of 1780 students. Med Educ (2010) 1.96
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer (2005) 1.71
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol (2009) 1.32
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol (2010) 1.31
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol (2010) 1.16
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol (2009) 1.15
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res (2011) 1.08
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Current and emerging targeted therapies for metastatic breast cancer. Cancer (2011) 1.08
Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol (2012) 1.06
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res (2007) 1.05
JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer (2006) 1.03
Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer (2009) 1.02
Sexual addiction or hypersexual disorder: different terms for the same problem? A review of the literature. Curr Pharm Des (2014) 1.01
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer (2011) 1.00
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol (2010) 1.00
Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics (2013) 0.99
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol (2014) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma. Eur J Cardiothorac Surg (2011) 0.97
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol (2014) 0.96
Circulating tumor cells in lung cancer. Acta Cytol (2012) 0.95
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res (2008) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Pharmacotherapy for smoking cessation: present and future. Curr Pharm Des (2011) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol (2008) 0.93
Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? J Clin Oncol (2008) 0.92
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol (2013) 0.92
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol (2007) 0.92
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Acute and long-term effects of cannabis use: a review. Curr Pharm Des (2014) 0.91
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol (2015) 0.90
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer (2013) 0.90
Paving the way to the cure of melanoma. Melanoma Res (2010) 0.90
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Thorac Oncol (2014) 0.89
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol (2014) 0.89
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol (2008) 0.89
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol (2011) 0.89
Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer (2009) 0.88
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle (2013) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
[Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma]. Ann Med Interne (Paris) (2003) 0.87
Retracted Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol (2011) 0.87
Motivation of French medical students to pursue surgical careers: results of national survey of 1742 students. J Visc Surg (2010) 0.86
Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict Biol (2011) 0.86
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
[Current data on methamphetamine]. Rev Prat (2012) 0.86
Thymic carcinomas: clinicopathologic study of 37 cases from a single institution. Virchows Arch (2013) 0.86
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85
Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. Curr Pharm Des (2014) 0.84
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. Clin Cancer Res (2013) 0.84
Is love passion an addictive disorder? Am J Drug Alcohol Abuse (2010) 0.84
Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.84
[Energy drinks: an unknown risk]. Rev Prat (2012) 0.84
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol (2010) 0.84
[Mephedrone: a new synthetic drug]. Presse Med (2013) 0.84
Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. J Thorac Oncol (2009) 0.84
Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int (2012) 0.84
Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol (2006) 0.84
Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol (2011) 0.83